Saadvik Raghuram Y/LinkedIn
Jun 25, 2025, 20:47
Saadvik Raghuram Y: FDA Approves Talectrectinib for ROS1-Positive Locally Advanced or Metastatic NSCLC
Saadvik Raghuram Y, Head of Department of Medical Oncology at Arete Hospitals, shared a post on X:
“FDA approves Talectrectinib for ROS1-positive locally advanced or metastatic NSCLC.
Response rates in TKI naive (85-90%)
ORR in patients with prior TKI (52%)
CNS response rates in TKI Naive (73%), prior TKI (63%)
Watch out for Dizziness, QTc”
More posts featuring Saadvik Raghuram Y on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jul 16, 2025, 17:55
Jul 16, 2025, 17:38
Jul 16, 2025, 17:37
Jul 16, 2025, 17:04
Jul 16, 2025, 16:51
Jul 16, 2025, 16:34
Jul 16, 2025, 16:18
Jul 16, 2025, 16:06